Abstract：
UNASSIGNED: About one-fifth of cannabis users, the most commonly used illicit substance, have cannabis use disorder (CUD). Psychiatric disorders and suicide are more common in these patients, and the disability-adjusted life years were reported to be 0.69 million. Pharmacotherapy for CUD is an unmet public health need, as current evidence-based therapies have limited efficacy.
UNASSIGNED: After explaining the pathophysiology of CUD, the effects of emerging pharmacological interventions in its treatment obtained from randomized controlled trials were reviewed in light of mechanisms of action. Superiority over control of cannabidiol, gabapentin, galantamine, nabilone plus zolpidem, nabiximols, naltrexone, PF-04457845, quetiapine, varenicline, and topiramate were observed through the cannabinoid, glutamatergic, γ-aminobutyric acidergic, serotonergic, noradrenergic, dopaminergic, opioidergic, and cholinergic systems. All medications were reported to be safe and tolerable.
UNASSIGNED: Adding pharmacotherapy to psychotherapy is the optimal treatment for CUD on a case-by-case basis. Drug development to add to psychotherapy is the main path, but time and cost suggest repurposing and repositioning existing drugs. Considering sample size, follow-up, and effect size, further studies using objective tools are necessary. The future of CUD treatment is promising.
UNASSIGNED: After explaining the pathophysiology of CUD, the effects of emerging pharmacological interventions in its treatment obtained from randomized controlled trials were reviewed in light of mechanisms of action. Superiority over control of cannabidiol, gabapentin, galantamine, nabilone plus zolpidem, nabiximols, naltrexone, PF-04457845, quetiapine, varenicline, and topiramate were observed through the cannabinoid, glutamatergic, γ-aminobutyric acidergic, serotonergic, noradrenergic, dopaminergic, opioidergic, and cholinergic systems. All medications were reported to be safe and tolerable.
UNASSIGNED: Adding pharmacotherapy to psychotherapy is the optimal treatment for CUD on a case-by-case basis. Drug development to add to psychotherapy is the main path, but time and cost suggest repurposing and repositioning existing drugs. Considering sample size, follow-up, and effect size, further studies using objective tools are necessary. The future of CUD treatment is promising.
摘要：
■大约五分之一的大麻使用者，最常用的非法物质，有大麻使用障碍（CUD）。精神病和自杀在这些患者中更为常见，据报告，残疾调整寿命年为69万。CUD的药物治疗是未满足的公共卫生需求，因为目前的循证疗法疗效有限。
■在解释了CUD的病理生理学之后，我们根据作用机制对从随机对照试验中获得的新兴药物干预对其治疗的影响进行了综述.优于控制大麻二酚，加巴喷丁,加兰他敏,纳比隆加唑吡坦,纳比肟,纳曲酮,PF-04457845,喹硫平,伐尼克林,通过大麻素观察到托吡酯，谷氨酸能,γ-氨基丁酸能，血清素能,去甲肾上腺素能,多巴胺能,opiopideric,和胆碱能系统。据报道，所有药物都是安全和可耐受的。
■在心理治疗中增加药物治疗是CUD的最佳治疗方法。药物开发是增加心理治疗的主要路径，但是时间和成本建议重新利用和重新定位现有的药物。考虑到样本量，后续行动,和效果大小，使用客观工具的进一步研究是必要的。CUD治疗的前景广阔。
■在解释了CUD的病理生理学之后，我们根据作用机制对从随机对照试验中获得的新兴药物干预对其治疗的影响进行了综述.优于控制大麻二酚，加巴喷丁,加兰他敏,纳比隆加唑吡坦,纳比肟,纳曲酮,PF-04457845,喹硫平,伐尼克林,通过大麻素观察到托吡酯，谷氨酸能,γ-氨基丁酸能，血清素能,去甲肾上腺素能,多巴胺能,opiopideric,和胆碱能系统。据报道，所有药物都是安全和可耐受的。
■在心理治疗中增加药物治疗是CUD的最佳治疗方法。药物开发是增加心理治疗的主要路径，但是时间和成本建议重新利用和重新定位现有的药物。考虑到样本量，后续行动,和效果大小，使用客观工具的进一步研究是必要的。CUD治疗的前景广阔。
